Zielgerichtete Therapien (beim Lungenkrebs) und die Treibermutationen

In this video, Nicoline Ehrhardt (patient and patient representative, ZielGENau e.V.) and PD Dr. Matthias Scheffler (UK Cologne) discuss what targeted therapy is and the role driver mutations play in it. Here, Dr. Scheffler provides an introduction to targeted therapies, including the distinction from immunotherapy. We also delve deeper into the role of biomarkers and driver mutations in cancer treatment. In this conversation, we also address the individual driver mutations and how certain mutations are typical for specific types of cancer. Therefore, it is so important that these mutations are identified during the diagnostic process so that highly effective targeted therapies can be used. Some mutations, such as those of EGFR, ALK, and RET, are already readily treatable with medication, while progress has only recently been made for others, such as KRAS. A film with Nicoline Ehrhardt (Board Member of ZielGENau e.V.) and PD Dr. Matthias Scheffler (Head of the Molecular Tumor Board UK Cologne, CIO ABCD) A film by the Strube Foundation All lung cancer films are a collaboration with ZielGENau e.V. and Nicoline Ehrhardt. 0:00 Intro 0:07 Targeted Therapy vs. Personalized Therapy vs. Precision Medicine 1:53 Biomarkers 2:46 Driver Mutations 3:37 Difference between Targeted Therapy and Immunotherapy 6:32 Wild Type 7:09 Oncogenes 7:40 Gene Mutations: Deletion, Insertion, Fusion 10:00 Are Driver Mutations Found in Every Type of Lung Cancer? 12:14 Driver Mutation in Adenocarcinoma 14:08 Expression 15:15 Driver Mutations for Which Drugs Are Available 19:19 Driver Mutations in Other Cancers